Are schedule exceptions rare for lyrica?

What makes schedule exceptions for Lyrica rare?

Lyrica (pregabalin) falls under Schedule V of the Controlled Substances Act. This classification applies because pregabalin has accepted medical uses and a lower potential for abuse than substances in Schedules I-IV.

How does the DEA decide whether a drug gets a lower schedule or an exemption?

The DEA evaluates five statutory factors when assigning schedules: actual or relative potential for abuse, evidence of abuse, risk of psychological or physical dependence, and current patterns of abuse. Those factors explained why Lyrica moved from unscheduled to Schedule V in 2005.

What happens if a state tries to reclassify or exempt Lyrica?

States rarely override federal scheduling. Most keep Lyrica as Schedule V to align with federal law. A few states have attempted stricter controls, but exemptions from Schedule V status remain rare because they would require overriding the DEA’s assessment of its abuse potential.

When does Lyrica’s patent expire?

Lyrica’s composition-of-matter patent expired in December 2018. The pediatric exclusivity extension gave it protection until June 2019. [1]

Who makes generic versions of Lyrica?

Several manufacturers now produce pregabalin generics, including Pfizer, which still owns active reissued patents on certain formulations.

Can biosimilars or generics enter before patent expiry?

Generics entered after the 2019 expiry. No true biosimilars exist because Lyrica is a small-molecule drug rather than a biologic.